Trials / Completed
CompletedNCT00139724
Evaluate Efficacy and Safety Of Tolterodine Extended Release Capsule Compared With Tolterodine Immediate Release Tablet
A Phase III Randomized, Double-Blind, Double Dummy, Multi-Center Study To Compare The Efficacy, Safety And Tolerability Of Tolterodine Extended Release Capsule With Tolterodine Immediate Release Tablet In Subjects With Symptoms Of Overactive Bladder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 260 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate efficacy of tolterodine extended release formulation compared with immediate release formulation in subjects with symptoms of overactive bladder
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tolterodine extended release capsule |
Timeline
- Start date
- 2005-05-01
- Primary completion
- 2006-10-01
- Completion
- 2006-10-01
- First posted
- 2005-08-31
- Last updated
- 2021-01-27
Locations
7 sites across 1 country: China
Source: ClinicalTrials.gov record NCT00139724. Inclusion in this directory is not an endorsement.